Rimegepant: First Approval
Compliance with Ethical Standards
Funding The preparation of this review was not supported by any external funding.
Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Lesley Scott is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.The
orally disintegrating tablet (ODT) formulation of rimegepant (NURTEC ODT®)
is a small molecule, highly-selective, calcitonin gene-related peptide
antagonist that was developed by Biohaven Pharmaceutical Holding Company Ltd as
an acute treatment for migraine. A conventional tablet formulation of the drug
is being investigated for the
acute treatment (under FDA review in the USA) and prevention of migraine and
the treatment of refractory trigeminal neuralgia. In February 2020, rimegepant
ODT received its first global approval in the USA for the acute treatment of
migraine (± aura) in adults. This article summarizes the
milestones in the development of rimegepant leading to its first global
approval for acute treatment of migraine (± aura) in adults
© Springer Nature Switzerland AG 2020
